Alacrita is pleased to announce that Michael Lombardo, PharmD, PhD, has joined our consulting team in the Cambridge, MA office.
With over a decade of experience in pharmaceutical sciences, Michael brings significant expertise in drug discovery, biomarker development, and small molecule therapeutics. His work in oncology and infectious diseases spans the full drug development lifecycle, from initial discovery to clinical validation and market launch.
In his new role, Michael will advise Alacrita clients on a range of R&D and business challenges.
“Michael's leadership in forging collaborations between prominent research institutions like Harvard Medical School, Dana-Farber, and MIT speaks volumes about his collaborative approach and dedication to advancing cutting-edge science. We are excited for him to bring his deep expertise in the field and his collaborative spirit to Alacrita, where he will undoubtedly make significant contributions to our clients' success,” said Alastair Southwell, Managing Partner at Alacrita Consulting.
Prior to joining Alacrita, most recently Michael led multiple biomarker projects at Boston Children's Hospital, advancing cancer diagnostics from discovery through clinical validation. His work contributed to the development of non-invasive diagnostics with the potential to significantly increase the 5-year survival rate in patients with triple-negative breast cancer and pancreatic cancer. At Harvard Medical School, Michael spearheaded antiviral drug discovery projects, leading collaborations with leading labs, including Nathanael Gray’s at Dana-Farber and Angela Koehler’s at MIT, to advance PROTAC targeted protein degraders to treat Hepatitis B infection and covalent inhibitors to target SARS-CoV-2.
Michael holds a PharmD and PhD from the University of Connecticut, completed a Pharmacy Practice Residency at Saint Francis Hospital and Medical Center, and received postdoctoral training at Harvard Medical School. His scientific and clinical work has contributed to 16 publications, 1 patent, and presentations at 9 international conferences.
» Click here to view Michael's full bio.
About Alacrita Consulting
Alacrita is a pharma and biotech consulting firm whose value to clients is founded on the first-hand experience of its subject-matter experts. Consultants who have spent their careers discovering, developing, manufacturing and commercializing drug products.
Alacrita’s core team leverages a purpose-built network of over 300 such experts who are brought onto project teams when their expertise matches the needs of the situation. This allows the firm to provide clients with precisely relevant support on a range of R&D and business issues, while offering the speed and flexibility expected from a professional consulting firm.
With over a decade of global, multi-disciplinary experience across a range of therapeutic areas and technologies, few firms match the breadth and depth in Alacrita’s expertise.